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A B S T R A C T
Purpose: West syndrome (WS) is a severe age-related acute epileptic encephalopathy of infancy
characterized by infantile spasms, hypsarrhythmia and psychomotor delay. The aim of this study was
to investigate if patients with WS had an altered autonomic output to the heart.
Methods: In 23 patients with WS the heart rate variability (HRV) was investigated by examining time-
and frequency-domain parameters of HRV at the time of the diagnosis of hypsarrhythmia and compared
to 22 age-matched controls. For the WS patients the same dataset was obtained and compared again
at the end of the study period, when hypsarrhythmia was no longer present.
Results: Compared to controls, patients with WS during hypsarrhythmia had signiﬁcantly lower SDNN
(the standard deviation of the NN interval, i.e. the square root of variance) (19.2 ms; p = 0.007, Mann–
Whitney’s U-Test) and total power (242 ms2; p = 0.044, Mann–Whitney’s U-Test) in the awake state,
indicating an abnormal autonomic output to the heart. Comparing the initial to the ﬁnal examination
demonstrated a signiﬁcant increase in the HRV parameters SDNN (31.3 ms) and total power (757 ms2;
p = 0.001 and p = 0.013, Wilcoxon Signed Ranked Test). In addition, at the ﬁnal examination the WS-
patients no longer differed signiﬁcantly from the controls.
Conclusion: Our data suggest that the initial reduction in HRV in patients at the time of onset of WS is
transient and related to the presence of hypsarrhythmia.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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West syndrome (WS) is a severe age-related acute epileptic
encephalopathy of early infancy. WS consists of the triad epileptic
(infantile) spasms, the abnormal electroencephalographic (EEG)
pattern of hypsarrhythmia and psychomotor delay [1].
Heart rate variability (HRV) serves as a useful and accepted
marker of the sympathetic–parasympathetic balance of the
autonomic nervous system to the heart. Low HRV is often an
indicator of abnormal and insufﬁcient modulation from the
autonomic nervous system [2].
Epileptic seizures can induce changes in the balance between
sympathetic and parasympathetic inﬂuence on the heart including
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suggested that a high sympathetic tone ictally and interictally is
the main cause of lower HRV and SUDEP [2,3].
A previous study with frequency-domain analysis of HRV in
children with West syndrome found patients to have a more
prominent low frequency component of HRV, suggesting a higher
sympathetic tone compared to controls [13].
In this study we investigated if hypsarrhythmia in West
syndrome may induce an altered autonomic output to the heart by
analysing 5-min segments of electrocardiogram (ECG) recorded
routinely together with the video-EEG at the time of diagnosis. The
RR-intervals were analysed in the time- and frequency-domain
and data were compared with data from age-matched controls. At
the end of the study period, when the WS patients no longer had
the EEG pattern of hypsarrhythmia or clinical spasms, HRV data
were re-analysed and compared to baseline values. Finally it was
investigated if possible alterations might have a correlation to the
clinical outcome.
To the best of our knowledge this is the ﬁrst study to investigate
how the autonomic nervous system to the heart is affected over
time in patients with WS.served.
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2.1. Patients
Twenty-three infants (11 females and 12 males, median age
6 months, range 3–15 months), diagnosed with West syndrome,
who were seen at the Department of Clinical Neurophysiology
from January 2005 through January 2012, were included in this
retrospective study. No patients were lost to follow up. Inclusion
criteria were an EEG showing hypsarrhythmia and a simultaneous
ECG of good quality. Routinely, the patients were followed with
serial EEGs to monitor the effect of treatment.
Patients were excluded if they had a story of heart disease or
conduction abnormalities on the ECG or if they were prescribed
with antiarrhythmic agents.
At the initial recording some patients were treated with
antiepileptic drugs but no patients had started treatment with
glucocorticoids.
2.2. Controls
Twenty-two age- and sex-matched infants (13 males, 9 females,
median age 6 months, range 3–14 months), who were referred
under the suspicion of having epilepsy but had a normal EEG and
ﬁnally were diagnosed as healthy, served as a control group.
2.3. EEG and ECG measurements
All EEGs were of minimum 30 min duration using the
international 10/20 system electrode array recorded on standard
digital commercial equipment. Almost all had simultaneous video-
recording to document clinical events. The historical recordings
were re-analysed by a neurophysiologist (HH) to conﬁrm the
original ﬁnding and to select characteristic epochs of hypsar-
rhythmia (chaotic pattern, high EEG-amplitude, epileptic dis-
charges, seizure patterns and/or series of infantile spasms from
the EEG and the simultaneous video). 5 min-segments of ECG-
recordings between seizures, awake and during sleep, were also
selected. Sleep was judged from the video and characteristic
EEG ﬁndings, if present. An evaluation of sleep stage was not
possible at time of diagnosis, due to the setting and severely
abnormal EEG pattern.
2.4. Measurement and analysis of HRV
Heart rate variability (HRV) was calculated from the duration
of RR intervals in the 5 min-ECG segment analysed. The RR interval
durations were measured using the programme LabChart 7
(Version 7.3.2) after automatic QRS complex detection (peak
determination method). All detected QRS complexes were veriﬁed
manually and corrected for artefacts. QRS complexes were
classiﬁed into normal or ectopic beats.
The tachygram (graphic presentation of RR-interval) was
visually inspected to detect trends in the data, ectopic beats
or other sudden changes, which could disturb especially the
frequency analysis.
The recording was graded using a score of 0 (no disturbances), 1
(less than 2% of aberrant beats), 2 (aberrant beats during less than
1/3 of the time series) or 3 (aberrant beats during more than 1/3 of
the time series). Recordings with a score of 1 and 2 were included
in all analyses while the rest were excluded from the analysis in the
frequency domain.
Analysis of heart rate variability in the time- and frequency
domains were done according to the standards of the Task Force of
the European Society of Cardiology and the North American Society
of Pacing and Electrophysiology [14].After QRS complex detection, the normal-to-normal (NN)
interval (i.e. all intervals between adjacent QRS complexes
resulting from sinus node depolarisations) was determined. The
R-wave peak was identiﬁed without any change to the recorded
signal due to the high signal-to-noise ratio in these recordings.
In the time domain median heart rate (beats per minute) and
SDNN (the standard deviation of the NN interval, i.e. the square
root of variance) were measured. SDNN is a statistical estimate
of overall HRV and reﬂects all the cyclic components responsible
for variability in the 5-min ECG recording [14]. As a substantial
occurrence of aberrant beats will affect the statistical analysis, the
SDNN was reported for the entire group of patients and,
in addition, for the group of patients with recordings scored
0 and 1, only.
In the frequency domain, spectral analysis of heart rate can
provide additional information on the autonomic function of the
heart. Power spectral density (PSD) analysis provides the basic
information of how power (i.e. variance) is distributed as a
function of frequency [14]. Frequency domain analysis was
performed using the non-parametric method of Fast Fourier
Transformation (FFT) with a Welch-window correction (formal).
The total power of the dataset was divided into the power of
variability in three standard frequency bands including high
frequency band (HF) ranging from 0.3 to 1.3 Hz, low frequency
band (LF, 0.04–0.3 Hz), very low frequency band (VLF  0.04 Hz).
The high frequency band limits were adjusted to match infant
respiratory sinus arrhythmia. In addition, power in the low- and
high-frequency bands were reported normalized to the total power
(n.u.: LF/(Total power  VLF)  100) and as the low-frequency/
high-frequency ratio (LF/HF). Vagal activity is the major contribu-
tor to the HF component, while the LF component is considered by
some authors as a marker of sympathetic modulation and by
others as a parameter including both vagal and sympathetic
inﬂuences [14].
2.5. Statistical methods
The data were analysed using the statistical package SPSS-20.0
for Mac. Descriptive statistics were given as medians (range) due to
the small number of individuals in each study group. A value of p
less than 0.05 was considered statistically signiﬁcant. Normality
of the distribution of data was assessed using the Kolmogorov–
Smirnov test, which suggested violation of the assumption of
normality. As a result, the non-parametric Mann–Whitney’s U-test
was applied for between-groups comparisons. In order to analyse
the change in the weekly recordings we tried to perform an
ANOVA, but this was not possible due to missing data points. For
that reason only the ﬁrst- and last EEG recording were included
and compared using the Wilcoxon Signed Rank Test.
The occurrence of aberrant beats in the recordings giving scores
0–3 were compared between groups. The distribution of scores
among the patients was compared to the distribution among
controls using the Mann–Whitney’s U-test.
2.6. Ethics
The retrospective data collection has been approved by The
Danish Data Protection Agency (No. 2007-58-0015).
3. Results
Clinical characteristics of the 23 patients with West syndrome
(WS) are shown in Table 1. Median age at onset was 6 months
(3–15 m). No signiﬁcant difference in gender and age between the
study group and the control group was found. The diagnostic work-
up showed that 15 had symptomatic WS and 8 had cryptogenic
Table 1
Proﬁles of patients with West syndrome.
Patient no. Aetiology Age at onset Medication during study period Clinical outcome
1 Periventricular leukomalacia 6 VGT 1
2 Cryptogenic 6 VGT, HCS, KGD, TPM, CZP 2
3 Cryptogenic 6 VGT, HCS, KGD 2
4 Cryptogenic 5 VGT, HCS 2
5 Cryptogenic 4 VGT, HCS 1
6 Fetal hypoxia 3 VGT, HCS, OXC 2
7 Tuberous sclerosis 8 VGT, TPM 2
8 Speciﬁc gene mutation 4 VGT, HCS, TPM, KGD 2
9 Perinatal haemorrhage 4 VGT, HCS, TPM, VPA, CZP 2
10 Periventricular leukomalacia 5 VGT, HCS, KGD, LEV 2
11 Tuberous sclerosis 6 VGT, HCS 1
12 Miller Diekers syndrome 6 VGT, HCS, OXC 2
13 Cryptogenic 4 VGT, HCS, KGD 2
14 Cortical dysplasia 5 VGT 2
15 Cryptogenic 7 VGT, HCS 1
16 Cryptogenic 7 VGT, HCS 1
17 Periventricular leukomalacia 8 VGT, HCS, LEV, TPM 2
18 Perinatal haemorrhage 8 VGT 2
19 Cortical dysplasia 4 VGT, HCS, OXC 2
20 Cryptogenic 10 VGT, HCS, VPA 1
21 Tuberous sclerosis 4 VGT 1
22 Tuberous sclerosis 5 VGT, TPM 2
23 Down’s syndrome 15 VGT, HCS 2
VGT, vigabatrin; HCS, hydrocortisone; KGD, ketogenic diet; TPM, topiramat; CZP, clonazepam; OXC, oxcarbazepine; VPA, valproate; LEV, levetiracetam clinical outcome:
1 = good, almost age-appropriate development (development corresponding to 70% or more); 2 = mental and/or physical retardation of varying degree.
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ment, while 16 had mental and/or physical retardation of varying
degree at follow up (Table 1).
At the time of the ﬁrst recording some of the children had just
started treatment with vigabatrin but none of the children had
started hydrocortisone (Table 1).
All 23 patients had hypsarrhythmia in their EEG at presentation
(week 1). After 2 weeks 10 patients continued to have hypsar-
rhythmia. The number of patients with hypsarrhythmia gradually
decreased to two patients after 6 weeks. Seven patients presented
clinically with infantile spasms during their ﬁrst EEG recording,
while one patient had infantile spasms documented in EEG after
2 weeks and in the following 6 weeks (Fig. 1). Two patients, who
still showed hypsarrhythmia after 6 weeks, continued to present
very abnormal hypsarrhythmia-like EEG patterns after 18 and
22 months, respectively, after which their diagnoses were changed
to a chronic encephalopathy syndrome.
Ten patients presented normalization in their last EEG
recording, while the remaining thirteen continued to have other
types of epileptiform abnormalities.Fig. 1. Number of patients with hypsarrhythmia (red) and seizures (green) during
the ﬁrst 6 weeks after presentation. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)At the time of diagnosis the ECG showed sinus rhythm in all
patients with WS. The median heart rate in the patients was
142 beats per minute (bpm) (111–196) when awake and 125 bpm
(100–157) during sleep. The controls had values of 139 bpm (103–
158) when awake and 123 bpm (92–144) during sleep, which did
not differ signiﬁcantly from that of the patients (p = 0.205 and
p = 0.721).
During the recordings no ectopic beats (characterized by a
shortened RR-interval followed by a compensatory increased RR-
interval) were seen. However in some recordings episodic changes
were found to disturb the recording, giving a sudden increase in
RR-interval and followed by a smaller increase in RR-interval of the
subsequent beats. Those changes were compatible with a sudden
change in sinoatrial conduction time. The ﬁrst recordings during
the awake state had signiﬁcantly lower scores of aberrant beats
in patients compared to controls (p = 0.036). During sleep this
difference was not signiﬁcant (p = 0.453). Recordings at the end of
the study did not differ signiﬁcantly in neither the awake state
or during sleep (p = 0.359 and p = 0.344). The distribution of scores
is shown in Table 2.
Comparisons of HRV characteristics between patients with WS
and control subjects during wakefulness are shown in Table 3 and
during sleep in Table 4.Table 2
Number of ECG-recordings with episodes of aberrant beats and the distribution of
recordings according to their score in the patients on their ﬁrst visit, on their last
visit and the score in controls. The scores were given both for recordings during the
awake state and during sleep.
Patients – ﬁrst
visit
Patients – last
visit
Controls
Score Awake Sleep Awake Sleep Awake Sleep
0 15 4 6 4 7 9
1 4 3 8 4 9 5
2 1 6 5 2 5 6
3 2 1 4 4 1 2
Total 22 14 23 14 22 22
Table 3
Comparison of heart rate variability parameters during wakefulness in the patients with West syndrome and controls.
Controls (n = 22) Patients: ﬁrst
EEG-recording
(n = 23)
Patients: last
EEG-recording
(n = 23)
P1
Comparison
between the
patients’ ﬁrst
EEG recording
and the controls
P2
Comparison
between the
patients’ ﬁrst
EEG recording
and their last
EEG recording
P3
Comparison
between the
patients’ last
EEG recording
and the controls
SDNN (ms) 31.0 (14.6–79.1) 19.2 (7.6–57.2) 31.3 (16.5–106) 0.007 0.001 0.482
SDNN* (ms) 25.1 (14.6–50.7) 18.2 (7.6–42.6) 27.6 (16.5–63.7) 0.054 0.028 0.569
Total power (ms2) 659 (167–2130) 242 (54–1643) 757 (192–3847) 0.044 0.013 0.380
LFnorm (n.u.) 84.5 (58.3–94.6) 81 (62–90) 60.1 (16.5–81.8) 0.661 0.753 0.559
HFnorm (n.u.) 15.5 (5.4–41.7) 19 (10.4–38) 20.8 (7.1–41.4) 0.661 0.753 0.792
LF/HF 5.5 (1.4–17.5) 4.2 (1.6–8.6) 2.7 (0.4–11.5) 0.661 0.463 0.726
Heart rate (bpm) 139 (103–158) 142 (111–196) 120 (88–172) 0.205 0.002 0.107
Data are expressed as medians (range). SDNN, the standard deviation of the NN interval (all patients); SDNN* (patients without aberrant heart beats); LFnorm, low frequency
power in normalized unit (LF/LF + HF); HFnorm, high frequency power in normalized unit (HF/HF + LF); LF/HF, ratio of LF component to HF component. P1: p-value obtained
using Mann–Whitney’s U-test. P2: p-value obtained using Wilcoxon test. P3: p-value obtained using Mann–Whitney’s U-test.
Table 4
Comparison of heart rate variability parameters during sleep in the patients with West syndrome and controls.
Controls (n = 22) Patients: ﬁrst
EEG-recording
(n = 15)
Patients: last
EEG-recording
(n = 13)
P1
Comparison
between the
patients’ ﬁrst
EEG recording
and controls
P2
Comparison
between the
patients’ ﬁrst
EEG recording
and their last
EEG recording
P3
Comparison
between the
patients’ last
EEG recording
and controls
SDNN (ms) 31.0 (7.9–98.6) 31.5 (12.4–75.3) 47.4 (16.9–107.2) 0.846 0.037 0.048
SDNN* (ms) 24.4 (7.9–98.6) 17.7 (12.4–38) 38.4 (16.9–41.8) 0.243 0.285 0.529
Total power (ms2) 592 (65–9660) 311 (152–861) 1496 (328–1592) 0.203 0.285 0.378
LFnorm (n.u.) 71 (14.9–92.5) 77.7 (68.9–82.7) 21.3 (10.1–84.7) 0.457 0.593 0.900
HFnorm (n.u.) 29 (7.5–85.1) 18 (15.3–25.9) 26.2 (9.9–54) 0.339 0.593 0.529
LF/HF 2.5 (0,2–12.3) 4.4 (2.9–4.8) 1.4 (0.2–8.6) 0.339 1.000 1.000
Heart rate (bpm) 123 (92–144) 125 (100–157) 103 (88–130) 0.721 0.005 0.003
Data are expressed as medians (range). SDNN, the standard deviation of the NN interval (all patients); SDNN* (patients without aberrant heart beats); LFnorm, low frequency
power in normalized unit (LF/LF + HF); HFnorm, high frequency power in normalized unit (HF/HF + LF); LF/HF, ratio of LF component to HF component. P1: p-value obtained
using Mann–Whitney’s U-test. P2: p-value obtained using Wilcoxon test. P3: p-value obtained using Mann–Whitney’s U-test.
Fig. 2. Total power (ms2) as a function of heart rate (bpm) for the patients with West
syndrome (blue) and controls (green). (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
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at presentation (ﬁrst EEG recording)
In the time domain, the SDNN was signiﬁcantly lower in
patients with WS compared to controls when awake in all patients
(19.2 ms (7.6–57.2) and 31.0 ms (14.6–79.1), p = 0.007, Mann–
Whitney’s U-test). When comparing the patients and controls
without arrhythmia the p value was 0.054.
In the frequency domain, only the total power was signiﬁcantly
lower in WS patients compared to controls (242 ms2 (54–1643)
and 659 ms2 (167–2130), p = 0.044, Mann–Whitney’s U-test).
There was no signiﬁcant difference in LF and LF/HF ratio.
During sleep no signiﬁcant differences between groups neither in
time domain parameters nor in the frequency domain were found.
A signiﬁcant difference in heart rate (HR) was seen both during
wakefulness and sleep in the WS patients, comparing the ﬁrst
EEG recording to the last with higher values at presentation with
West syndrome. The patients and the controls did not differ
signiﬁcantly in HR neither when awake nor during sleep. The
relationship between total power and HR was investigated using
Pearson product-moment correlation coefﬁcient after manual
removal of extreme outliers in the patients and controls and a
negative correlation between the two variables was found (WS
patients: rho = 0.64, N = 22, p = 0.001, controls: rho = 0.74,
N = 20, p < 0.001). However, the regression lines for the correlation
between total power and HR in the two groups were different,
with WS patients showing lower total power than controls in the
lower range of HR (Fig. 2). To evaluate if this difference in total
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in HR, WS patients and controls were divided in two groups with
HR < 130 and HR > 130, and total power at ﬁrst examination was
analysed in the two groups. A signiﬁcant difference in total power
between WS patients and controls was still present (p < 0.005,
Mann–Whitney’s U-Test).
3.2. Comparison between patients with West syndrome at
presentation (ﬁrst EEG recording) and at the end of the study period
At their ﬁnal EEG recording patients had a median heart rate
of 120 bpm (88–172) when awake and 103 bpm (88–130) during
sleep.
Comparing values of the time domain parameter SDNN
evolving from ﬁrst to last awake EEG recording in all the patients,
a signiﬁcantly higher variability was seen (19.2 ms (7.6–57.2) to
31.3 ms (16.5–106), p = 0.001, Wilcoxon Signed Ranked Test). The
same was found in the patient group without a signiﬁcant amount
of aberrant beats (score 0 and 1) (p = 0.028). Total power was
higher as well (242 ms2 (54–1643) to 757 ms2 (192–3847),
p = 0.013, Wilcoxon Signed Ranked Test). The change in LFnorm,
LF/HF-ratio and HFnorm did not reach statistical signiﬁcance
(p = 0.753, p = 0.463 and p = 0.753) (Table 3). Also, with sleep a
change during the disease course with a signiﬁcantly higher value
of SDNN was found (31.5 ms (12.4–75.3) to 47.4 ms (16.9–107.2),
p = 0.037, Wilcoxon Signed Ranked Test) in the entire group of
patients. In the group without a signiﬁcant amount of aberrant
beats, this was no longer found to be signiﬁcant (p = 0.285).
3.3. Comparison between the patients’ ﬁnal EEG recording and the
controls
At the time of the patients’ ﬁnal awake EEG recording, both
SDNN and total power values had increased to levels not
signiﬁcantly different from those of the controls (SDNN: 31.3 ms
(16.5–106) p = 0.482, total power: 757 ms2 (192–3847) p = 0.380,
Mann–Whitney’s U-Test). The other parameters HFnorm, LFnorm and
LF/HF-ratio were also comparable with the controls.
In recordings during sleep SDNN was signiﬁcantly higher
among the patients (31.0 ms (7.9–98.6) and 47.4 ms (16.9–107.2)
p = 0.048). All the other HRV parameters were not signiﬁcantly
different from the recordings of the controls.
When investigating whether any underlying known aetiology
changed the measures of HRV no difference was found in the ﬁrst
(total power: (922 ms2 (655–3723) vs. 701 ms2 (192–3847),
p = 0.270, Mann–Whitney’s U-Test), SDNN: (29.6 ms (26.4–63.7)
vs. 27.6 ms (16.5–60), p = 0.221, Mann–Whitney’s U-Test)) or the
last recording (total power: 922 ms2 (655–3723) vs. 701 ms2 (192–
3847) p = 0.270, SDNN: 29.6 ms (26.4–63.7) vs. 27.6 ms (16.5–60)
p = 0.211, Mann–Whitney’s U-Test).
Finally, no signiﬁcant difference in total power during the
awake state was found in patients with a good clinical outcome
(242 ms2 (64–647)) compared to patients with a poor clinical
outcome at presentation (234 ms2 (54–2832), p = 1.000, Mann–
Whitney’s U-test).
4. Discussion
The key ﬁnding of this study is that patients during the initial
phase of West syndrome, when hypsarrhythmia is present, had
reduced measures of HRV (SDNN and total power), especially when
they were awake, compared to controls.
It is suggested that a reduced frequency of aberrant heart beats
partly accounts for the change in variability found between study
groups. The aberrant beats are considered normal ﬁndings in
infants and were indeed less frequent in patients during the initialillness, when awake. We conclude that the reduced variability as
well as the reduced frequency of aberrant beats are the results of
a change in autonomic inﬂuence on the heart during this severe
epileptic condition at the beginning of the disease.
As we ﬁnd no difference in heart rate between groups, mere
tachycardia could not account for the reduced variability.
With 23 patients with WS included, this cohort is the largest
reported. Hattori et al. [13] also investigating autonomic function
in 15 patients with West syndrome by frequency domain
measures of HRV, found that patients with WS had a signiﬁcantly
higher low frequency (LF) power and a non-signiﬁcantly higher
high frequency (HF) power compared to controls. However, they
also found that the distribution of LF power in the WS patients
and controls overlapped, indicating that not all the patients
had autonomic changes. In addition, they found no difference in
LF/HF-ratio between patients and controls [13]. Contrary to
their ﬁndings, we did not ﬁnd a signiﬁcantly lower value of LF in
normalized units when awake or during sleep in WS patients
compared to the controls.
Other studies have similarly shown an autonomic dysfunction
in patients with other types of epileptic syndromes. Kolsal et al.
[15] found reduced parasympathetic activity with lower LF and HF
in 20 children with refractory epilepsy. Hallioglu et al. [9] reported
signiﬁcantly decreased values of SDNN interictally in 92 patients,
of whom 55% had partial seizures and 41% generalized seizures.
Tomson et al. [16] found a reduced HRV (SDNN and total power)
and decreased low frequency power and lower LF/HF-ratio in
patients with complex partial seizures with a temporal lobe focus
compared to controls. This ﬁnding is similar to our ﬁnding of low LF
power and lower LF/HF-ratio in patients with West syndrome
compared to controls. El-Sayed et al. [17] found a decrease in SDNN
in 25 epileptic children during the interictal period, where
10 patients presented generalized seizures and the rest had
localization-related epilepsy. Ferri et al. [3] conducted a study of
11 children with partial epilepsy during sleep and reported an
overall lower HRV in both time- and frequency-domain param-
eters. In contrast, Evrengul et al. [2] found an increase in SDNN in
43 patients with generalized tonic–clonic seizures. However, West
syndrome is a unique electroclinical syndrome on its own.
The second important ﬁnding is that WS-patients, at the end
of the acute disease course, at their ﬁnal EEG recording, had
recovered from the reduced HRV parameters, which were no
longer signiﬁcantly different from those of the controls. Actually
they showed higher values of SDNN and total power especially
during sleep compared to controls. This ﬁnding suggests that the
abnormal autonomic cardiac inﬂuence is transient or reversible
and directly related to epileptiform activity. Whether this recovery
is indeed a result of disease resolution or a lingering effect from
antiepileptic treatment cannot be decided.
Hattori et al. [13] showed the treatment with hydrocortisone to
be correlated to an increase in HRV. The same effect could be
present in our cohort. As a subgroup analysis was not possible, we
could only speculate as to whether this treatment promoted the
recovery of the HRV or had a lingering side effect.
We were not able to detect any prognostic signiﬁcance of the
initial recordings concerning neither the existence of an underly-
ing aetiology nor the long term clinical outcome of the patients.
One limitation of this study is the lack of controlled breathing
and measurement of the respiratory frequency (RF), as it is well
known that RF inﬂuence heart rate variability, and especially
variability in the high frequency band (HF). The WS patients and
the controls did not differ signiﬁcantly in HR neither when awake
nor during sleep, but there was a diverging correlation between
total power and HR in WS patients and controls, especially in the
lower range of HR, with WS patients showing lower total power
than controls. In a sub-group analysis dividing the WS patients and
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in total power was still found between WS patients and controls
in both groups, suggesting that HR is not the sole reason for
differences in total power in the two groups at ﬁrst examination.
Individuals with the highest scores of total power and the lowest
scores of HR were those with age ranging from 8 to 15 months. Age
is known to inﬂuence HRV [18–20]. Massin et al. [18] found a
progressive maturation of the autonomic nervous system through-
out childhood in 210 healthy children aged from 3 days to 14 years
and Silvetti et al. [19] investigated 103 healthy children and
adolescents and found that parameters of HRV increased with
age and gender. This might explain our results showing higher
total power with higher age. This maturation could increase the
variability during the observation period and could, therefore,
account for some of the recovery of variability in the patients.
Another limitation of the study was that we did not control for
the general health condition of the patients or controls, including
if they were dehydrated or had electrolytic derangement, which
might inﬂuence the function of the autonomic nervous system and
thus the heart rate variability.
5. Summary
In the present study of time- and frequency-domain analysis of
heart rate variability (HRV) obtained from a 5-min ECG recording, it
was demonstrated that infants with West syndrome have reduced
HRV at the onset of the disease, when hypsarrhythmia dominates,
compared to controls. It was also shown, that this reduction in HRV is
temporary, since at the end of the study period, there was no
signiﬁcant difference between WS patients and controls.
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